metabolics

BioAge CEO's big plans for 'multi-disease impact' of NLRP3 drug

After axing its lead obesity asset, BioAge has turned its attention to attacking inflammation in its pursuit of treatments for aging-related illnesses

Will Maddox May 14, 2026 11:00am

Septerna launches with $100M and GPCR pioneer co-founder

Jan 27, 2022 7:00am

FDA hits Viking clinical hold over mix-up in phase of trial

Jan 24, 2022 8:35am

Lilly extends JPM collab theme in $1B Evotec pact, Abbisko deal

Jan 18, 2022 11:30am

Applied pumps brakes on FDA application after request for data

Jan 4, 2022 3:30pm

Eli Lilly pens $1.5B biobucks pact with China's Regor

Dec 10, 2021 7:40am